CONTINUING STUDY ON AIDS-RELATED OPPORTUNISTIC PATHOGENS

描述：(改编自《调查者摘要》。)初级阶段 这项提议的目标是继续一项已经确立的研究 南部研究部William Barrow博士(PI)之间的合作 和巴斯德研究所的纳林·拉斯托吉博士(Co Pi)。这个 合作始于巴罗博士的休假。 拉斯托吉的实验室是Fogarty高级国际的一部分 自1992、1994年起成为研究员。该奖学金的目的是 加深对禽类分枝杆菌复合体的了解 关于致病性、毒力和多重耐药。那些 研究设计为与NIH的两项拨款进行互动，这两项拨款是 是国际和平研究所研究计划的一部分，因此在 继续为这些赠款提供资金。此外，还有几份手稿 这些研究工作的结果就是出版。拉斯托吉博士一直在 在巴黎的巴斯德研究所工作了十多年。去年 他搬到了法国瓜德罗普岛上的巴斯德研究所， 他目前是结核病和分枝杆菌的负责人 单位。作为这一举措的结果，与拉斯托吉博士的合作 为涉及艾滋病相关的扩展研究提供了独特的条件 病原体，如禽类分枝杆菌和结核分枝杆菌。这是特别的 当人们考虑多重耐药(MDR)的影响时，重要的是 结核分枝杆菌菌株的重要性以及早期发现和 一旦这些菌株出现，就对它们进行监测。另一组 对HIV+感染者构成威胁的分枝杆菌是禽类分枝杆菌 复杂，不仅对多种药物具有耐药性，而且不是 关于它的致病性，大家都很了解。作为数字的 艾滋病病毒感染者在全球范围内增加，这一点尤为重要 建立一个全球监测系统，以隔离和遏制 结核分枝杆菌多药耐药菌株，并评估新的治疗方法 不仅治疗结核分枝杆菌耐多药菌株，而且治疗结核分枝杆菌耐多药菌株。 也有鸟巢复合体。这项提案的具体目标将为1) 禽分枝杆菌和结核分枝杆菌的分离及特性研究 瓜德罗普和瓜德罗普的艾滋病毒阳性和艾滋病毒阴性患者 周边加勒比地区，2)获取以下地区的药物敏感性模式 每种菌株，以及3)禽型和结核分枝杆菌的特性 利用限制性内切酶片段长度多态性进行进一步研究 致病性和耐药性。此次合作不仅将 允许PI加强他目前由NIH资助的与M。 Avium还允许他将他的研究努力扩展到另一种 重要的艾滋病相关病原体，结核分枝杆菌。

DESCRIPTION: (Adapted from the Investigator's Abstract.) The primary goal of this proposal is to continue an already established research collaboration between Dr. William Barrow (PI), Southern Research Institute, and Dr. Nalin Rastogi (Co PI) of the Institut Pasteur. The collaboration began when Dr. Barrow served a sabbatical leave in Dr. Rastogi's laboratory as a part of a Fogarty Senior International Fellowship from 1992, 1994. The purpose of that fellowship was to develop a better understanding of the Mycobacterium avium complex with regard to pathogenicity, virulence and multiple drug resistance. Those studies were designed as interactive with two NIH grants that were a part of the PI's research program, and as a result were important in the continued funding of those grants. In addition, several manuscripts were published as a result of those research efforts. Dr. Rastogi has been with the Institut Pasteur in Paris for more than ten years. Last year he moved to the Institut Pasteur on the island of Guadeloupe, France, where he is currently the Chief of the Tuberculosis and Mycobacteria Unit. As a result of that move, the collaboration with Dr. Rastogi offers a unique situation for extended studies involving AIDS related pathogens such as M. avium and M. tuberculosis. This is particularly important when one considers the impact of multiple drug resistant (MDR) strains of M. tuberculosis and the importance of early detection and monitoring of these strains once they develop. Another group of mycobacteria that poses a threat to HIV+ individuals is the M. avium complex, which is not only resistant to multiple drugs, but which is not well understood with regard to its pathogenicity. As the numbers of HIV+ individuals increases worldwide, it is particularly important to develop a global surveillance system for the isolation and containment of MDR strains of M. tuberculosis, and to evaluate new methods for treatment of MDR strains of not only M. tuberculosis but those of the M. avium complex as well. The specific aims of this proposal will be to 1) isolate and characterize strains of M. avium and M. tuberculosis form HIV positive and HIV negative patients in Guadeloupe and the surrounding Caribbean area, 2) obtain drug susceptibility patterns for each strain, and 3) characterize strains of M. avium and M. tuberculosis by restriction fragment length polymorphism for further studies on pathogenicity and drug resistance. This collaboration will not only allow the PI to enhance his current NIH funded research efforts with M. avium but also allow him to expand his research efforts to another important AID related pathogen, M. tuberculosis.